Berlin,  May 20, 2025 - Cantourage Group SE (hereinafter ‘Cantourage’, ISIN:DE000A3DSV01, www.cantourage.com), Europe's leading listed medical cannabis company, reports an EBITDA margin of 11 to 13% for the first quarter of 2025 based on preliminary, internal figures (unaudited, non consolidated). Revenues in the same period amounted to more than EUR 25 million; as of the end of April, cumulative revenues already exceeded EUR 36 million, confirming both the economic scalability of Cantourage's business model and the continued strongdemand in its core markets.

‍

Press contact at Cantourage:

Manuel Taverne| taverne@cantourage.com